Volume 7.45 | Nov 19

Mammary Cell News 7.45 November 19, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
Propagation of Estrogen Receptor-Positive and Estrogen-Responsive Normal Human Breast Cells in Culture
The authors set out to identify markers for isolating estrogen receptor-positive cells and to expand what appear to be post-mitotic primary cells into exponentially growing cultures. [Nat Commun] Full Article
Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now
PUBLICATIONS (Ranked by impact factor of the journal)

An EGFR/Src-Dependent β4 Integrin/FAK Complex Contributes to Malignancy of Breast Cancer
Scientists demonstrated for the first time physical and functional interactions between β4 integrin and FAK that influence breast cancer malignancy. [Sci Rep] Full Article

EpCAM Expression in Breast Cancer Cells Is Associated with Enhanced Bone Metastasis Formation
Investigators examined the roles of epithelial cell adhesion molecule (EpCAM) in the development of bone metastasis of breast cancer by using well-characterized animal models. Morphological and real-time RT-PCR data showed that the EpCAM-negative and -positive cell populations isolated from breast cancer cell lines exhibited mesenchymal and epithelial phenotypes, respectively. [Int J Cancer] Abstract

XBP1 Regulates the Biosynthetic Capacity of the Mammary Gland During Lactation by Controlling Epithelial Expansion and Endoplasmic Reticulum Formation
To assess the role of XBP1 in mammary epithelial cells, researchers studied floxed XBP1 female mice lacking or expressing the Cre recombinase under the control of the ovine β-lactoglobulin promoter. [Endocrinology] Abstract

Emerging Prognostic Markers Related to Mesenchymal Characteristics of Poorly Differentiated Breast Cancers
The authors investigated the correlation among poorly differentiated carcinoma, epithelial to mesenchymal transition phenomenon, and expression of NF-kB, Sonic hedgehog, K-RAS, and PTX3 in breast cancer in 100 breast biopsies. [Tumor Biol] Abstract

miR130b-Regulation of PPARγ Coactivator-1α Suppresses Fat Metabolism in Goat Mammary Epithelial Cells
Scientists utilized an improved microRNA (miRNA) detection assay, S-Poly-(T), to profile the expression of miRNAs in the goat mammary gland in different periods, and found that miR-130b was abundantly and differentially expressed in goat mammary gland. Additionally, overexpressing miR-130b impaired adipogenesis while inhibiting miR-130b enhanced adipogenesis in goat mammary epithelial cells. [PLoS One] Full Article

Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines – An Isobolographic Analysis
Scientists investigated the influence of valproic acid and suberoylanilide hydroxamic acid, alone or in combination with cisplatin on proliferation, induction of apoptosis and cell cycle progression in MCF7, T47D and MDA-MB-231 human breast carcinoma cell lines. [PLoS One] Full Article

Gain-of-Function p53 Mutant with 21-bp Deletion Confers Susceptibility to Multidrug Resistance in MCF-7 Cells
Researchers investigated the role of a deletion spanning codons 127-133 in the p53 gene and its association with the proliferation, metastasis and drug resistance of MCF-7 cells. [Int J Mol Med] Abstract


A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor Positive Metastatic Breast Cancer
This trial was conducted to determine the maximum tolerated dose and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive breast cancer. [Clin Cancer Res] Abstract

A Multicenter Prospective Phase II Trial of Neoadjuvant Epirubicin, Cyclophosphamide, and 5-Fluorouracil (FEC100) followed by Cisplatin–Docetaxel with or without Trastuzumab in Locally Advanced Breast Cancer
Investigators evaluated the efficacy and safety profile of FEC100 followed by cisplatin/docetaxel with and without trastuzumab as primary chemotherapy for patients with locally advanced breast cancer. [Cancer Chemother Pharmacol] Abstract

Dissociation Enzymes For Optimized Human Mammary Tissue Dissociation and Culture - FREE Protocols
Constitutive Activation of STAT3 in Breast Cancer Cells: A Review
This review provides a full spectrum of signal transducer and activator of transcription 3 (STAT3)’s involvement in breast cancer by consolidating the knowledge about its role in breast cancer development at multiple levels: its differential regulation by different receptor signaling pathways, its downstream target genes, and modification of its transcriptional activity by its co-regulatory transcription factors. [Int J Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Epic Sciences Partners with University of Pennsylvania’s Abramson Cancer Center on Cancer Therapy Discoveries through Liquid Biopsy
Epic Sciences, Inc. announced a collaboration with the Abramson Cancer Center of the University of Pennsylvania on multiple studies to explore biomarkers, identified by analysis of circulating tumor cells at a single cell resolution, that are predictive of response to personalized cancer therapeutics. [Epic Sciences, Inc.] Press Release

Enterome and Gustave Roussy Enter into a Microbiome-Based Collaboration to Develop Novel Immunotherapy Solutions to Treat Cancer
Enterome Bioscience SA announced that it has entered into a collaborative development agreement with Gustave Roussy. They aim to develop of a new generation of drugs and non-invasive monitoring tools of the gut microbiome in immuno-oncology. [Enterome Bioscience SA] Press Release

From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells.
Watch now.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Stem Cells and Organoids as Models of Tissue Differentiation and Disease
January 12, 2016
London, United Kingdom

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Research Scientist – Cancer Therapy (Massachusetts General Hospital)

NEW Postdoctoral Position – Epigenetics and Cancer (Moffitt Cancer Center)

Cancer Biologist (Wake Forest Baptist School of Medicine)

Postdoctoral Research Fellow – Ovarian and Breast Cancer (Fred Hutchinson Cancer Research Center)

Academic Breast Pathologist (Beth Israel Deaconess Medical Center)

Group Leader Position – Cancer Research (Oslo University Hospital)

Postdoctoral Fellow – Metastatic Breast Cancer (Purdue University Center for Cancer Research)

Biological Imaging Scientist – 3D Cellular Models of Organs and Disease (University of Pittsburgh Drug Discovery Institute)

Postdoctoral Fellow – Tumor Dormancy (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Fellow – Metastatic Breast Cancer (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us